Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-BapiFcRn
- Development stage
- Preclinical
- Lead developer
- Uppsala University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]F-BapiFcRn is a radiolabeled monoclonal antibody tracer designed for positron emission tomography (PET) imaging of amyloid-beta (Aβ) pathology in Alzheimer's disease. It is based on bapineuzumab, a humanized antibody that targets the N-terminus of the Aβ peptide. The antibody has been engineered with specific mutations in its Fc region to reduce its binding affinity for the neonatal Fc receptor (FcRn). This modification facilitates rapid clearance of the tracer from the blood, thereby reducing background radioactivity and improving the signal-to-noise ratio for brain imaging. Labeled with the radioisotope fluorine-18, [18F]F-BapiFcRn is used in preclinical research to visualize Aβ plaques and to serve as a reference for evaluating the brain uptake of bispecific antibodies that utilize receptor-mediated transcytosis.
- Other names
- 18F-labeled bapineuzumab with reduced FcRn binding[18F]F-bapineuzumab-FcRn-
02
Targets
Amyloid-beta aggregate (N-terminal epitope)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on [18F]F-BapiFcRn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]F-BapiFcRn.